UBS Group Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $660.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target increased by investment analysts at UBS Group from $595.00 to $660.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. UBS Group’s target price points to a potential upside of 0.38% from the stock’s previous close.

A number of other analysts have also recently weighed in on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, October 23rd. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Royal Bank Of Canada raised their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 29th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 1st. Finally, Jefferies Financial Group increased their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a report on Wednesday, August 27th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $796.57.

Regeneron Pharmaceuticals Trading Up 1.6%

Shares of NASDAQ REGN opened at $657.53 on Friday. The company has a market cap of $69.69 billion, a price-to-earnings ratio of 15.75, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $834.42. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock’s 50 day simple moving average is $588.03 and its 200 day simple moving average is $568.04.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The firm had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm’s revenue was up .9% on a year-over-year basis. During the same period in the prior year, the business earned $12.46 EPS. Equities research analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.02% of the stock is currently owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Activest Wealth Management lifted its holdings in Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 21 shares during the last quarter. Costello Asset Management INC acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $27,000. Saudi Central Bank bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $27,000. Salomon & Ludwin LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter valued at approximately $27,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals during the second quarter valued at approximately $31,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.